scholarly journals Sentinel Node Biopsy Alone versus Completion Axillary Node Dissection in Node Positive Breast Cancer: Systematic Review and Meta-Analysis

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
Rachna Ram ◽  
Jasprit Singh ◽  
Eddie McCaig
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Sentinel Node ◽  
Axillary Dissection ◽  
Meta Analysis ◽  
Axillary Node ◽  
Axillary Node Dissection ◽  
Controlled Trials ◽  
Positive Sentinel Node ◽  
Node Dissection

Introduction. There has been recent interest in validity of completion axillary node dissection after a positive sentinel node. This systematic review aims to ascertain if sentinel lymph node dissection alone was noninferior to axillary lymph node dissection for breast cancer patients who have a positive sentinel node.Method. A systematic review of the electronic databases Embase, MEDLINE, and Cochrane Register of Controlled Trials was carried out. Only randomised trials that had patients with positive sentinel node as the study sample were included in the meta-analysis using the reported hazard ratios with a fixed effect model.Results. Three randomised controlled trials and five retrospective studies were identified. The pooled effect for overall survival was HR 0.94, 95% CI [0.79, 1.19], and for disease free survival was HR 0.83, 95% CI [0.60, 1.14]. The reported rates for locoregional recurrence were similar in both groups. The surgical morbidity was found to be significantly more in patients who had underwent axillary dissection.Conclusion. Amongst patients with micrometastasis in the sentinel node, no further axillary dissection is necessary. For patients with macrometastasis in the sentinel node, it is reasonable to consider omitting axillary dissection to avoid the morbidity of the procedure.

scholarly journals Sentinel node biopsy in the breast cancer: Possibility of the avoidance of axillary node dissection

2002 ◽  
Vol 10 (3) ◽  
pp. 192-195
Author(s):  
Andrija Golubovic ◽  
Bratislav Stojiljkovic ◽  
Aleksandar Plzak ◽  
Zoran Radovanovic ◽  
Aleksandar Patrnogic
Keyword(s):  
Breast Cancer ◽  
Sentinel Node ◽  
Sentinel Node Biopsy ◽  
Operative Treatment ◽  
Shoulder Joint ◽  
Axillary Dissection ◽  
Axillary Node ◽  
Axillary Node Dissection ◽  
Node Dissection ◽  
Node Biopsy

(Conclusion) This researching, and many others, indicates that in certain patients (especially T1a and T1b), under precise criteria, when SN metastases are not present, axillary dissection in the breast cancer (10, 22) and all its consequences (lymphoedeama, numbness, pain, limited movement in the shoulder joint) could be avoided. We should remember that nowadays at least 50% of women undergo axillary nodes dissection within the breast cancer operative treatment because of histopathologically negative nodes.

scholarly journals EP.TH.166Evaluation of the impact of the COVID-19 pandemic on the practice of axillary node dissection

2021 ◽  
Vol 108 (Supplement_7) ◽  
Author(s):  
Grant Harris ◽  
Alice Townend ◽  
Madgi Youssef
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Sentinel Node ◽  
Axillary Node ◽  
Axillary Node Dissection ◽  
Delayed Presentation ◽  
Positive Sentinel Node ◽  
Node Dissection ◽  
Node Positive ◽  
The Impact

Abstract Aims The Association of Breast Surgery's "COVID-altered" guidance for management of breast cancer during the COVID-19 pandemic, includes that neoadjuvant chemotherapy was only to be used only in inoperable disease and not to downstage the axilla. Delayed presentation with increased nodal involvement was also a concern. We aim to establish if axillary node dissection (AND) increased in the context of pandemic. Methods Patients undergoing surgery for breast cancer were identified from theatre coding in a UK breast unit. Pre-COVID (March 2018 - February 2020) and COVID pandemic (March - September 2020) cohorts were compared. Indication, tumour receptor status, neoadjuvant chemotherapy (NAC) and deviation from routine practice were ascertained for those undergoing AND. Trust Caldicott and audit department approval was obtained for this retrospective review of practice. Results AND was performed in 20.2% (23/114) of breast cancer operations during the pandemic compared with 18.97% (78/411) pre-COVID. Indication for AND during the pandemic and pre-COVID respectively - clinically node positive 82.6%/79.4%; positive sentinel node biopsy 4.3%/17.9%; recurrence or metastases from contralateral cancer 13%/2.5%. NAC preceded AND in 30% of cases in both cohorts. NAC for one node positive HER2+ cancer was omitted due to the pandemic and another patient had adjuvant chemotherapy omitted for a HER2+ cancer with a single positive sentinel node mandating an AND which yielded no further positive nodes. Conclusions The COVID-19 pandemic has not significantly impacted rates of AND in our practice. However, we identified 2 patients who may have avoided AND with normal chemotherapy protocols.

Pathologic Evaluation of Axillary Dissection Specimens Following Unexpected Identification of Tumor Within Sentinel Lymph Nodes

2011 ◽  
Vol 135 (1) ◽  
pp. 131-134
Author(s):  
Jessica Gutierrez ◽  
Daniel Dunn ◽  
Margit Bretzke ◽  
Eric Johnson ◽  
John O'Leary ◽  
...  
Keyword(s):  
Lymph Node ◽  
Sentinel Node ◽  
Tumor Cells ◽  
Axillary Dissection ◽  
Frozen Section ◽  
Axillary Node ◽  
Axillary Node Dissection ◽  
Node Dissection ◽  
Isolated Tumor Cells ◽  
Sentinel Nodes

Abstract Context—Axillary lymph node dissection has been the standard of care after identification of a positive sentinel lymph node for breast cancer patients. Objective—To determine the likelihood of non–sentinel lymph node involvement for patients with negative sentinel node by frozen section, who are subsequently found to have tumor cells in the sentinel node by permanent section levels and/or cytokeratin immunohistochemistry. Design—One hundred three patients with invasive breast cancer exhibiting negative frozen section evaluation of their sentinel node, but later found to have isolated tumor cells (n  =  46), micrometastasis (n  =  46), or metastases (n  =  11) in their sentinel node by permanent sections or immunohistochemistry, were enrolled in this prospective cohort study and underwent completion axillary dissection. Results—Six of 46 patients (13%) with isolated tumor cells in their sentinel node, 15 of 46 patients (33%) with micrometastasis in their sentinel node, and 2 of 11 patients (18%) with metastasis in their sentinel node had additional findings in the nonsentinel nodes. These findings resulted in a pathologic stage change in 2 patients. Predictors of positive nonsentinel nodes were 2 or more positive sentinel nodes (P  =  .002), sentinel nodes with micrometastasis versus isolated tumor cells (P  =  .03), and those with angiolymphatic invasion (P  =  .04). Conclusions—Our findings lend support to axillary node dissection for patients with micrometastasis or metastasis in their sentinel nodes. However, studies with clinical follow-up are needed to determine whether axillary node dissection is necessary for patients with isolated tumor cells in sentinel nodes.

Sign in / Sign up

Export Citation Format

Share Document